Evaluation of Bi-Lateral Co-Infections and Antibiotic Resistance Rates among COVID-19 Patients in Lahore, Pakistan

Azka Rizvi 1, Muhammad Umer Saeed 2, Ayesha Nadeem 2, Asma Yaqoob 3, Ali A. Rabaan 4,5,6,*, M., Muhammed A. Bakhrrebah 7, Abbas Al Mutair 8,9,10,11, Saad Alhumaid 12,*, Mohammed Aljeldah 13,*, Basim R. Al Shammar 14, Hawra Albatay 15, Ameen S. S. Alwashmi 15,*, Firzan Nainu 16,*, Yousef N. Alhashem 17,*, Muhammad Naveed 18,*, and Naveed Ahmed 16,19,*

Abstract: Background and Objective: Bacterial infections are among the major complications of many viral respiratory tract illnesses, such as influenza and coronavirus disease-2019 (COVID-19). These bacterial co-infections are associated with an increase in morbidity and mortality rates. The current observational study was conducted at a tertiary care hospital in Lahore, Pakistan among COVID-19 patients with the status of oxygen dependency to see the prevalence of bacterial co-infections and their antibiotic susceptibility patterns. Materials and Methods: A total of 1251 clinical samples were collected from already diagnosed COVID-19 patients and tested for bacterial identification (cultures) and susceptibility testing (disk diffusion and minimum inhibitory concentration) using gold standard diagnostic methods. Results: From the total collected samples, 234 were found positive for different bacterial isolates. The most common isolated bacteria were Escherichia coli (E. coli) (n = 62) and Acinetobacter baumannii (A. baumannii) (n = 47). The E. coli isolates have shown the highest resistance to amoxicillin and ampicillin, while in the case of A. baumannii, the highest resistance was noted against tetracycline. The prevalence of methicillin resistant Staphylococcus aureus (MRSA) was 14.9%.
carbapenem resistant *Enterobacteriaceae* (CRE) was 4.5%, and vancomycin resistant *Enterococcus* (VRE) was 3.96%. Conclusions: The results of the current study conclude that empiric antimicrobial treatment in critically ill COVID-19 patients may be considered if properly managed within institutional or national level antibiotic stewardship programs, because it may play a protective role in the case of bacterial co-infections, especially when a patient has other AMR risk factors, such as hospital admission within the previous six months.

**Keywords:** *Enterobacteriaceae*; bacterial infections; antibiotic stewardship; hospital acquired infections; antibiotic resistance

1. Introduction

The novel coronavirus disease-2019 (COVID-19) has caused a global pandemic of severe respiratory tract illness [1,2]. The causative agent for this lethal disease is SARS-CoV-2 [3]. This disease made many hospitalized patients more critical, and COVID-19 cases became higher in a very short time period. It resulted in 445 million (M) reported cases and 6 M deaths worldwide [4]. Out of which, cases from Pakistan accounted for 1.15 M and 30,265 deaths [5]. The high transmissibility and associated mortality rates have raised concerns among clinicians and scientists [6,7].

During the incubation period, the virus is transmissible and upon infection, the virus induces viremia which causes fever, pharyngalgia, tiredness, diarrhea, and other symptoms [8,9]. This comprises the incubation period (1–14 days, usually 3–7 days) and early illness phases [10]. In the later stage, patients become hyper-coagulable and D-Dimer-based coagulation factors become aberrant [11]. Many other factors like demographics, immune status of the patient, treatment options, and secondary infections also contribute to the disease progression and prognosis of the disease, with secondary infection being at the top [12]. The use of empirical therapy in hospitalized COVID-19 patients has been reported widely in the literature leading to high antimicrobial resistance rates (AMR) among the bacterial isolates [12]. This raised a major concern among clinicians when deciding on treatment options for critical patients. The high AMR rates are another rising concern worldwide, and attempts are being made to tackle this problem [13].

In addition to the primary SARS-CoV-2 infection during the current COVID-19 pandemic, several secondary comorbidities are developing and significantly increasing the fatality rate [14]. Bacterial and fungal co-infections among them are critical, causing the death of many COVID-19 patients [5]. Pathogens that cause respiratory co-infection include viruses, bacteria, fungi, and other common pathogens [15]. Bacteria are one of the most often isolated organisms responsible for secondary co-infection. The bacterial co-infections may significantly increase the overall mortality among COVID-19 patients [4]. However, due to a lack of staff during the COVID-19 pandemic, many hospitals and healthcare facilities were unable to make all of the necessary diagnoses using the gold standard diagnostic techniques [9]. Secondary infections have been reported in 10–15% of the positive cases of COVID-19. Moreover, the incidence of these infections was higher among critically ill COVID-19 patients [4]. Of these co-infected patients, those who received invasive procedures accounted for up to 70% of the patients [14]. Secondary infections associated with COVID-19, especially in hospitalized patients, pose a great risk to the COVID patients as well as other (COVID-negative) patients, as there is a risk of spill-over of infectious bugs to the community [5].

Therefore, prolonged antibiotic treatment for secondary infections in COVID patients is of great public health concern [2]. The present retrospective observational study was designed to study the appearance of secondary bacterial infections associated with COVID-19 and their antimicrobial susceptibility patterns among patients with no oxygen support, oxygen support, and on ventilator, so that an informed decision can be made in choosing the appropriate treatment and patient management strategies. The purpose of the study
was to help clinicians in the empirical therapy and infection control department of hospitals manage the spread of infectious bugs.

2. Materials and Methods

2.1. Sample Collection

Samples included in the current study were processed after the request from a clinician suspecting a secondary infection among hospitalized COVID-19 patients based on their signs and symptoms during their illness or treatment course, and not necessarily upon admission. The COVID-19 status of the patients was confirmed using nasopharyngeal swabs-based polymerase chain reaction (PCR) tests before the admission of patients in COVID-19 allocated wards. Samples were collected aseptically in sterile containers from a tertiary care hospital in Lahore, Pakistan during the period from 24 July 2021 to 31 October 2021. Samples were collected by following the standard protocol for COVID-19 infection and transferred to a microbiology lab under refrigeration conditions for microbiological testing. Pre-defined criteria and a data collection sheet were established which included the patient’s demographic details, and comorbidities.

2.2. Isolation and Identification of Bacterial Isolates

All of the clinical samples (except urine samples) were inoculated on a set of culture media plates (blood agar, chocolate agar, and MacConkey agar plates) and incubated at 37 °C. The urine samples were inoculated on cysteine lactose electrolyte deficient (CLED) agar. Gram smears were prepared for all specimens except urine samples, while the wet smear examination was performed for urine samples to observe the presence of pus cells. The Gram stain smears of sputum samples were observed for the presence of pus cells counted to support the assumption of possible secondary bacterial infection in combination with signs and symptoms of the patient.

After 24 h of incubation at 37 °C, the culture plates were observed for bacterial growth and positive samples were selected for further laboratory processing. Culture plates without bacterial growth were re-incubated for another 24 h at 37 °C and observed for bacterial growth again. Negative culture samples were reported as negative for bacterial growth after 48 h, while the blood samples were incubated and checked for 7 consecutive days and re-inoculated after every 2 days to observe for any bacterial or fungal growth. The isolated organisms from the respiratory samples can be colonizers, but considering the immunocompromised status of patients, signs, and symptoms, cultures that were sent by clinicians suspecting bacterial infection (in COVID-19 positive patients) based on clinical signs and symptoms of the patients were included in the study [16,17].

After obtaining the growth, the morphology of each bacterial colony was observed and noted. Colonial morphology combined with Gram stain results and biochemical tests such as catalase, coagulase, oxidase, triple sugar iron (TSI), urease, analytical profile index (API) 20E, API 20NE, API Staph, and API Strept were employed to identify the organisms. A description of each biochemical test used has been given in the Table 1.

In the current study, the possibility of asymptomatic bacteriuria was kept in mind as the asymptomatic bacteriuria patients lacked the appearance of signs and symptoms that might be linked to the presence of bacteria in the urine. The assessment and treatment of symptomatic bacteriuria or urinary tract infections (UTIs) are very different from this, and urine cultures could be used to diagnose asymptomatic bacteriuria. A catheterized specimen or one that has been appropriately obtained using a clean-catch technique may be acceptable. The Infectious Diseases Society of America (IDSA) says that a bacterial infection is active when there are \(10^5\) colony forming units (CFU)/mL of one type of bacteria in the urine. Furthermore, the presence of >4 pus cells also ruled out the possibility of neglecting the asymptomatic bacteriuria [15]. Furthermore, the presence of pathogenic bacteria in upper respiratory tract samples was defined as an upper respiratory tract infection, while the presence of pathogenic bacteria in lower respiratory tract samples was defined as lower
respiratory tract infections, and the presence of bacteria in the blood samples was defined as bacteremia.

**Table 1.** Description of biochemical tests used.

| Name of the Test          | Description                                                                 |
|---------------------------|-----------------------------------------------------------------------------|
| Catalase                  | Used to differentiate between *Staphylococcus* spp. and *Streptococcus* spp. |
| Coagulase                 | Used to differentiate between *Staphylococcus aureus* and other *Staphylococcus* spp. |
| Oxidase                   | Used to identify *Pseudomonas* spp., *Burkholderia* spp., and *Stenotrophomonas* spp. |
| Citrate, Indole, TSI, and Urease | Used to identify organisms based on their ability to utilize the substrates in each test. |
| API strips (API 20E, API 20NE, API staph, and API strept) | API strips comes with a range of biochemical tests that generate a code for each isolate and a database that identifies the organism using the code. |

2.3. *Antibiotic Susceptibility Testing (AST)*

Isolated bacterial isolates were processed for AST by the disc diffusion method as per the recommendations by the Clinical Laboratory Standard Institute (CLSI) guidelines [18]. To perform the AST, MacFarland of 0.5 concentration was prepared using a density check technique for each of the isolates. This suspension was then spread on Muller Hinton (MH) agar plates and the antibiotics were placed on them according to CLSI guidelines, followed by incubation at 37 °C for 24 hrs. After the 24 h incubation, a zone of inhibition (ZOI) for each antibiotic was recorded as Resistant (R), Intermediate (I), and Sensitive (S). The ZOIs against the tested antibiotics were followed from the CLSI guidelines [15].

The tested antibiotics for Gram-positive isolates were amikacin, ampicillin, tetracycline, ciprofloxacin, tobramycin, gentamicin, teicoplanin, vancomycin, chloramphenicol, fusidic acid, linezolid, cefoxitin, clindamycin, erythromycin, nitrofurantoin, fosfomycin, azithromycin, levofloxacin, and cotrimoxazole-trimethoprim. Antibiotics used for Gram-negative isolates were amikacin, tobramycin, gentamicin, tetracycline, ciprofloxacin, levofloxacin, amoxicillin-clavunate, ceftriaxone, cefazidime, cefepime, cefixime, cefuroxime, cotrimoxazole-trimethoprim, nitrofurantoin, fosfomycin, nalidixic acid, imipenem, meropenem, colistin, polymyxin b, minocycline, and piperacillin-tazobactam.

To validate the results of AST, American Type Culture Collections (ATCC) were used such as *E. coli* 25922, *Staphylococcus aureus* (*S. aureus*) 29213, *Enterococcus faecalis* (*E. faecalis*) 29212, and *Staphylococcus epidermidis* (*S. epidermidis*) 25923.

2.4. *Statistical Analysis*

All of the obtained data were entered into Microsoft Office Excel spreadsheet version 2016 (Microsoft, Washington, DC, USA), Minitab (Pennsylvania State University, USA), and SPSS version 26.0 (IBM, New York, NY, USA). After finishing with the data entry in data sheets, descriptive statistics were run on the data to obtain the absolute numbers (*n*) and was reported in percentages (%).

3. *Results*

3.1. *Demographic Characteristics of Study Population*

From the total 1251 studied patients, 1081 patients did not need oxygen, *n* = 74 were on ventilator, and *n* = 96 were oxygen dependent. The population of infected males was higher as compared to the female population in all three groups of the study, i.e., oxygen dependent (*n* = 38), oxygen independent only (*n* = 658), and on ventilator (*n* = 45). The highest number of COVID-19 infected patients were between the ages of 30 and 50 years.
The characteristics of the COVID-19 patients with no oxygen support (NOS), oxygen support (OS), and ventilator dependent (VD), admitted to hospital are given in Table 2.

Table 2. Clinical and demographic characteristics of study population.

| Variables          | Characteristics of Study Population |
|--------------------|-------------------------------------|
|                    | No Oxygen Support (n = 1081) | Oxygen Support (n = 96) | Ventilator Dependent (n = 74) |
|                    | f  | %     | f  | %     | f  | %     |
| Age                |    |       |    |       |    |       |
| <30                | 331| 30.62%| 15 | 15.63%| 13 | 17.57%|
| 30–50              | 527| 48.75%| 34 | 35.42%| 27 | 36.49%|
| >50                | 223| 20.63%| 47 | 48.96%| 34 | 45.95%|
| Gender             |    |       |    |       |    |       |
| Male               | 658| 60.87%| 56 | 58.33%| 45 | 60.81%|
| Female             | 423| 39.13%| 40 | 41.67%| 29 | 39.19%|
| Underlying Disease |    |       |    |       |    |       |
| Diabetes mellitus  | 130| 12.03%| 11 | 11.96%| 10 | 13.51%|
| Hypertension       | 134| 12.40%| 10 | 10.87%| 12 | 16.22%|
| Kidney diseases    | 142| 13.14%| 25 | 27.17%| 18 | 24.32%|
| Gastrointestinal disorders | 128 | 11.84% | 14 | 15.22% | 9  | 12.16%|
| Liver disease      | 201| 18.59%| 17 | 18.48%| 13 | 17.57%|
| None               | 346| 32.01%| 19 | 19.79%| 12 | 16.22%|

f = frequency; % = percentage; n = number of samples/isolates/responses.

3.2. Sample-Wise Prevalence of Positive Bacterial Culture among COVID-19 Patients

Among all the collected samples, the highest positivity rate was recorded among tracheal aspirate which was 4.88%, followed by urine samples (4.56%). On the other hand, the lowest positivity rate was observed for pus samples followed by wound swabs (Table 3, Figure 1). The pus samples were collected using swabs from the deepest part of the wound avoiding the superficial microflora, and swabs were soaked in pus (if possible). The UTIs were seen in a total of 203 patients, while n = 157 were suffering from upper respiratory tract infection, n = 328 from lower respiratory tract infection, and n = 443 from bacteremia.

Table 3. Sample-wise prevalence of positive samples for pathogens, among COVID-19 patients.

| Samples                              | Positive Samples |
|--------------------------------------|------------------|
|                                      | f    | %    |
| Blood (n = 443)                      | 31   | 2.48 |
| Sputum (n = 157)                     | 39   | 3.12 |
| Bronchoalveolar lavage (n = 92)      | 26   | 2.08 |
| Urine (n = 203)                      | 57   | 4.56 |
| Wound swab (n = 41)                  | 12   | 0.96 |
| Tracheal aspirate (n = 236)          | 61   | 4.88 |
| Pus (n = 79)                         | 08   | 0.61 |

f = frequency, % = percentage, n = number of samples/isolates/responses.
3.3. Antibiotic Susceptibility Testing

Out of 234 positive samples, only 39 were Gram-positive isolates, while the rest of the 195 were Gram-negative isolates. Among the Gram-negative isolates were Klebsiella pneumonia, E. coli, A. baumannii, Pseudomonas aeruginosa (P. aeruginosa), Proteus vulgaris, Klebsiella oxytoca (K. oxytoca), Enterobacter cloacae, Stenotrophomonas maltophilia, Citrobacter freundii, and Serratia liquefaciens. Organisms with at least more than 10 isolates were processed for sensitivity. Enterococcus faecalis was the most commonly isolated organism among the Gram-positive bacteria which accounted for 22 of all Gram-positive isolates. The antibiotic resistance pattern for Gram-positive isolates is given in Table 4.

Table 4. Antibiotic resistance patterns among Gram-positive isolates.

| Antibiotics          | Staphylococcus aureus (n = 10) | Staphylococcus aureus (n = 22) |
|----------------------|-------------------------------|-------------------------------|
|                      | NOS  | OS  | VD  | NOS  | OS  | VD  |
| Amikacin             | 2.3  | 4.8 | 6.1 | NT   | NT  | NT  |
| Chloramphenicol *    | 10.2 | 10.8| 12.5| NT   | NT  | NT  |
| Cefoxitin            | 14.4 | 14.6| 15.7| NT   | NT  | NT  |
| Ciprofloxacin        | 63.3 | 70.1| 84.7| 70.5 | 83.8| 84.0|
| Co-trimoxazole       | 15.9 | 8.2 | 7.4 | NT   | NT  | NT  |
| Clindamycin          | 32.8 | 29.6| 28.2| NT   | NT  | NT  |
| Erythromycin *       | 70.4 | 50.5| 46.3| 55.7 | 70.1| 79.8|
| Fusidic acid *       | 13.2 | 9.3 | 8.0 | NT   | NT  | NT  |
| Gentamicin           | 4.8  | 7.6 | 7.9 | NT   | NT  | NT  |
| Linezolid            | 0.0  | 0.0 | 0.0 | NT   | NT  | NT  |
| Penicillin           | NT   | NT  | NT  | 10.4 | 12.0| 14.1|
| Tetracycline         | 56.0 | 56.2| 58.6| 46.1 | 53.5| 57.2|
| Tobramycin           | 15.0 | 15.4| 17.1| NT   | NT  | NT  |
| Levofloxacin         | 76.3 | 62.6| 63.1| NT   | NT  | NT  |
| Vancomycin           | 0.0  | 0.0 | 0.0 | 3.5  | 3.9 | 4.5 |

* Not included in urinary isolates. NOS: no oxygen support; OS: oxygen support; VD: ventilator dependent; n = number of samples/isolates/responses.
Among 39 Gram-positive isolates, 22 were *E. faecalis*; 10 were *S. aureus*; while the remaining 7 isolates consisted of *S. epidermidis*, *Streptococcus pneumoniae* (*S. pneumoniae*), and *Streptococcus spp*. Organisms with at least 10 isolates were included in the study.

Among the Gram-positive isolates, the highest resistance rate was noted against ciprofloxacin, while no bacterial isolate was found resistant to linezolid. Vancomycin was found to be as effective as linezolid against *S. aureus*, while some resistance (ranging from 1.2 to 5.2% among NOS, OS, and VD) was observed when tested against *E. faecalis*. Among the aminoglycosides group of antibiotics, amikacin was found to be the most effective antibiotic with a very low resistance rate (2.3 to 6.1%) among NOS, OS, and VD patients (Table 5).

### Table 5. Antibiotic resistance patterns among *Enterobacteriaceae*.

| Antibiotics                | *Escherichia coli* (n = 62) | Klebsiella pneumoniae (n = 35) |
|----------------------------|-------------------------------|-------------------------------|
|                            | NOS OS VD                      | NOS OS VD                      |
| Ampicillin                 | 98.2 100 100                   | NT NT NT                       |
| Amoxicillin clavunate      | 88.7 90.3 90.6                 | 90.0 93.4 94.7                |
| Amikacin                   | 12.0 13.8 14.2                 | 13.2 15.4 16.8                |
| Ceftriaxone                | 42.1 54.5 55.3                 | 64.1 68.9 70.0                |
| Cefuroxime                 | 57.3 67.1 70.2                 | 79.0 83.2 85.6                |
| Cefixime                   | 57.3 67.1 70.2                 | 77.1 84.5 88.4                |
| Chloramphenicol *          | 48.1 54.5 59.8                 | 67.5 68.9 70.5                |
| Ciprofloxacin              | 52.8 58.2 58.6                 | 87.6 90.8 93.6                |
| Co-trimoxazole             | 24.2 27.3 30.9                 | 30.2 33.3 35.1                |
| Gentamicin                 | 38.3 42.7 46.3                 | 57.7 62.7 68.4                |
| Fosfomycin **              | 11.2 14.3 15.8                 | NT NT NT                       |
| Imipenem                   | 4 4.4 5.2                      | 4.3 4.6 4.7                   |
| Meropenem                  | 3.9 4.3 5.1                    | 4.2 4.6 4.7                   |
| Nitrofurantoin **          | 13.5 15.6 17.2                 | 42.5 56.4 59.0                |
| Piperacillin-tazobactam    | 18.0 21.4 25.7                 | 20.6 23.6 29.6                |
| Tetracycline               | 14.7 16.8 22.3                 | 45.2 52.4 56.7                |
| Tobramycin                 | 35.8 38.3 43.6                 | 51.3 55.5 57.7                |
| Colistin                   | 0.0 0.0 0.0                    | 0.0 0.0 0.0                   |
| Polymyxin B                | 0.0 0.0 0.0                    | 0.0 0.0 0.0                   |

* Not included in urinary isolates. ** Only reported in urinary isolates. NT: not tested; NOS: no oxygen support; OS: oxygen support; VD: ventilator dependent; n = number of samples/isolates/responses.

Out of 195 Gram-negative isolates, *Proteus vulgaris* (n = 1), *K. oxytoca* (n = 4), *Enterobacter cloacae* (n = 2), *Stenotrophomonas maltophilia* (n = 2), *Citrobacter freundii* (n = 3), and *Serratia liquefaciens* (n = 1) were not included in the study because of a low number of isolates.

Among Gram-negative isolates, *E. coli* was found most resistant to ampicillin (NOS = 98.2%, OS = 100%, and VD = 100%), followed by amoxicillin-clavunate (NOS = 88.7%, OS = 90.3%, and VD = 90.6%). The highest resistance was also observed for amoxicillin-clavunate, when tested against *K. pneumonia* (NOS = 90.0%, OS = 93.4%, and VD = 94.7%). Carbapenem resistance was slightly higher for *K. pneumonia* (NOS = 16.7%, OS = 17.2%, and VD = 18%) as compared to *E. coli* (NOS = 15.1%, OS = 15.6%, and VD = 16.7%) (Table 6).

*Acinetobacter baumannii* showed the most resistance against the cephalosporin group, and among cephalosporin, the highest resistance was observed against ceftriaxone (100%) among NOS, OS, and VD. The highest sensitivity of *A. baumannii* was observed when tested against colistin (100% sensitive among NOS, OS, and VD). *P. aeruginosa* isolates showed high susceptibility to carbapenems and aminoglycosides, while the lowest susceptibility was noted against fluoroquinolones.
Table 6. Antibiotic resistance patterns among non-Enterobacteriaceae.

| Antibiotics         | Resistance Percentage (%) | Acinetobacter baumannii (n = 47) | Pseudomonas aeruginosa (n = 38) |
|---------------------|---------------------------|----------------------------------|----------------------------------|
|                     | NOS | OS | VD | NOS | OS | VD |
| Amikacin            | 33.5 | 34.8 | 37.5 | 12.2 | 12.8 | 14.6 |
| Ceftazidime         | 82.3 | 85.1 | 86.8 | 44.6 | 55.7 | 56.4 |
| Ciprofloxacin       | 78.1 | 84.3 | 85.7 | 81.12 | 88.2 | 88.6 |
| Levofloxacin        | 72.6 | 81.4 | 84.8 | NT | NT | NT |
| Co-trimoxazole      | 81.2 | 90.2 | 93.1 | NT | NT | NT |
| Gentamicin          | 80.3 | 88.4 | 90.0 | 13.4 | 14.7 | 17.5 |
| Imipenem            | 61.01 | 65.1 | 65.8 | 16.3 | 17.4 | 17.9 |
| Meropenem           | 59.2 | 64.1 | 64.6 | 16.3 | 17.3 | 17.6 |
| Piperacillin-tazobactam | 68.0 | 78.5 | 84.8 | 17.2 | 18.6 | 19.0 |
| Tetracycline        | 85.7 | 93.4 | 96.2 | NT | NT | NT |
| Tigecycline         | 1.2 | 1.3 | 1.3 | NT | NT | NT |
| Tobramycin          | 2.5 | 5.8 | 8.8 | 0.0 | 0.0 | 0.0 |
| Colistin            | 0.0 | 0.0 | 0.0 | NT | NT | NT |
| Polymyxin B         | 0.0 | 0.0 | 0.0 | NT | NT | NT |
| Cefepime            | 83.2 | 83.5 | 85.7 | 42.4 | 54.2 | 57.9 |

NOS: no oxygen support; OS: oxygen support; VD: ventilator dependent; n = number of samples/isolates/responses.

4. Discussion

Severe Acute Respiratory Syndrome SARS-CoV-2 due to the corona virus novel strain’s COVID-19 pandemic led to serious bacterial co-infections, especially in intensive care unit-admitted patients [5,19]. For the current study, 1251 COVID-19 positive patients were recruited, out of which most infected patients were male who were on life support oxygen (289) and 238 were on a ventilator. The highest positivity rate was observed in tracheal aspirate samples. Secondary infections were observed in 31% of ICU patients and 10% of all patients in a Wuhan investigation of 41 individuals [4].

A previous study from Wuhan indicated that 11/68 (16%) of 68 patients who died had secondary illnesses, while no further information was provided [20]. In the present study, out of 1251 positive COVID-19 patients, 234 (18.72%) were having a secondary bacterial infection. Another study in Italy found that of 16,654 critically ill patients who died of a SARS-CoV-2 infection, 11% had bacterial and fungal co-infections [21]. In a previously conducted study, Streptococcus pneumoniae, S. aureus, K. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, A. baumannii, Legionella pneumophila, and Clamydia pneumoniae were the most commonly detected co-pathogens of SARS-CoV-2 clearly showing an abundance of Gram-positive bacteria [22]. As compared to the current study, the prevalence of Gram-negative bacteria was more than Gram-positive, and the most common isolate was E. coli. Both Gram-positive isolates tested positive for resistance to ciprofloxacin, the most common antibiotic, whereas neither sample tested positive for linezolid resistance. For E. faecalis, vancomycin was found to be no less effective or no more effective than linezolid in terms of S. aureus resistance (range from 1.2 to 5.2% among NOS, OS, and VD).

Results of the previous study from Lahore, Pakistan found that the most common bacterial infections among COVID-19 patients admitted in the SICU were caused by E. coli (32%) [9]. The E. coli was also the most commonly isolated bacteria among the hospitalized COVID-19 patients [5]. These results are consistent with the results of the current study, as in the current study the E. coli was the most prevalent organism detected in different samples.
from critically ill COVID-19 patients. However, the findings of Wolfe and colleagues are different from ours, as the most commonly isolated organism among Gram-negatives in their study was *K. pneumoniae* and among Gram-positives, *S. aureus* was the most commonly isolated [23]. In another study conducted by Chong et al. all the organisms were suspected to be causing co-infections, but they suspected them to be hospital acquired as these organisms (*A. baumannii, K. pneumoniae, E. coli*, etc.) are usually responsible for causing such infections [24].

The results of the current study showed that *A. baumannii* isolates were highly resistant to all tested antibiotics, which were similar to the results of a study conducted by Vijay et al. in which 47% of the infected patients were infected with MDR organisms, and among them *A. baumannii* showed the highest resistance against all tested antibiotics [25]. In the current study, resistance to amikacin has ranged from 2.3% to 6.1% among NOS, OS, and VD, making it the most effective aminoglycoside. Meanwhile, Gram-negative bacterial isolates from blood and urine were found to be highly resistant to amoxicillin/clavulanic acid, ampicillin, and erythromycin.

MRSA and MSSA were among the Gram-positive pathogens that were isolated, and they were sensitive to vancomycin, teicoplanin, tigecycline, linezolid, and daptomycin, among other antibiotics in a previously published study [20]. The prevalence of MRSA in our study was 14.9%, which is comparable to the results of another study conducted by Hassan Mahmoudi et al. according to which it was 13.96% [15]. Another study reported an increase in the prevalence of MRSA from 3.53% to 25.30% in COVID-19 pathogens [26].

Most of *A. baumannii’s* resistance was found in the cephalosporin group, with the highest level of resistance found in ceftriaxone. When *A. baumannii* was tested against colistin, it was shown to be the most sensitive (100 percent sensitive among NOS, OS, and VD). *P. aeruginosa* isolates showed a high resistance rate against fluoroquinolones. However, the most effective antibiotics were carbapenem and aminoglycosides. On the other hand, in another published research study, *P. aeruginosa* and *E. coli* were the bacteria that were most frequently isolated as multi-drug resistant (MDR) and related with hospital acquired superinfections [27]. A similar finding was also reported in another study, according to which *E. coli* was found to be highly resistant to trimethoprim/sulfamethoxazole and piperacillin/tazobactam [28].

5. Conclusions

Patients infected with SARS-CoV-2 are frequently found to have co-infections with a variety of bacteria, which have been shown to have a substantial impact on the severity and fatality rates of COVID-19. However, our understandings of co-infecting organisms, their interactions with one another, and their eventual interactions with the hosts are limited. Furthermore, viral co-infection promotes bacterial adhesion; disrupts the tight junction and epithelial barrier integrity, allowing bacteria to transmigrate across cells; and alters both innate and adaptive immune responses, making the lungs more vulnerable to SARS-CoV-2 infections in the future.

**Author Contributions:** Conceptualization, N.A. and M.N.; methodology, A.R., M.U.S. and A.N.; software, M.U.S. and A.N.; validation, M.A.B., A.A.M. and S.A.; formal analysis, A.R.; investigation, M.A.; resources, H.A., A.S.S.A. and F.N.; data curation, N.A.; writing—original draft preparation, A.R., Y.N.A. and F.N.; writing—review and editing, A.Y., B.R.A.S., S.A., M.A. and A.S.S.A.; visualization, N.A.; supervision, M.N.; N.A. and A.A.R.; project administration, N.A. and A.A.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (Human Research Ethics Committee) of the University of Central Punjab, Code: UCP/FOLS/210717-8 approved on 17 June 2021.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.
Data Availability Statement: The data related to the current study will be available upon a reasonable request to the corresponding author.

Acknowledgments: The authors would like to thank King Abdulaziz City for Science and Technology (KACST) for the support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Platto, S.; Xue, T.; Carafoli, E. COVID19: An announced pandemic. Cell Death Dis. 2020, 11, 1–13. [CrossRef]

2. Ahmed, N.; Ritvi, A.; Naeem, A.; Saleem, W.; Ahmed, A.; Parveen, S.; Ilyas, M. COVID-19 and public awareness. Prof. Med. J. 2020, 27, 1710–1716. [CrossRef]

3. Bengoechea, J.A.; Bamford, C.G. SARS-CoV-2, bacterial co-infections, and AMR: The deadly trio in COVID-19? EMBO Mol. Med. 2020, 12, e12560. [CrossRef]

4. Kariyawasam, R.M.; Julien, D.A.; Jelinski, D.C.; Larose, S.L.; Rennert-May, E.; Conly, J.M.; Dingle, T.C.; Chen, J.Z.; Tyrrell, G.J.; Ronksley, P.E. Antimicrobial resistance (AMR) in COVID-19 patients: A systematic review and meta-analysis (November 2019–June 2021). Antimicrob. Resist. Infect. Control 2022, 11, 1–18. [CrossRef]

5. Ahmed, N.; Khan, M.; Saleem, W.; Karobari, M.I.; Mohamed, R.N.; Heboyan, A.; Rabaan, A.A.; Mutair, A.A.; Alhumaid, S.; Alsadiq, S.A. Evaluation of bi-lateral co-infections and antibiotic resistance rates among COVID-19 patients. Antibiotics 2022, 11, 276. [CrossRef]

6. Tomczyk, S.; Taylor, A.; Brown, A.; De Kraker, M.E.; El-Saed, A.; Alshamrani, M.; Hendriksen, R.S.; Jacob, M.; Lofmark, S.; Perovic, O. Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: A global survey. J. Antimicrob. Chemother. 2021, 76, 3045–3058. [CrossRef]

7. Langford, B.J.; So, M.; Raybardashan, S.; Leung, V.; Westwood, D.; MacFadden, D.R.; Soucy, J.-P.R.; Daneman, N. Bacterial coinfection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020, 26, 1622–1629. [CrossRef]

8. Li, T.; Lu, H.; Zhang, W. Clinical observation and management of COVID-19 patients. Emerg. Microbes Infect. 2020, 9, 687–690. [CrossRef]

9. Zeshan, B.; Karobari, M.I.; Afzal, N.; Siddiq, A.; Basha, S.; Basheer, S.N.; Peeran, S.W.; Mustafa, M.; Daud, N.H.A.; Ahmed, N. The usage of antibiotics by COVID-19 patients with comorbidities: The risk of increased antimicrobial resistance. Antibiotics 2021, 11, 35. [CrossRef]

10. McAloon, C.; Collins, Á.; Hunt, K.; Barber, A.; Byrne, A.W.; Butler, F.; Casey, M.; Griffin, J.; Lane, E.; McEvoy, D. Incubation period of COVID-19: A rapid systematic review and meta-analysis of observational research. BMJ Open 2020, 10, e039652. [CrossRef]

11. Lei, S.; Jiang, F.; Su, W.; Chen, C.; Chen, J.; Mei, W.; Zhan, L.-Y.; Jia, Y.; Zhang, L.; Liu, D. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EclinicalMedicine 2020, 21, 100331. [CrossRef]

12. Haque, M.; Meyer, J.C.; Godman, B. Potential ways to address antimicrobial resistance across India and wider exacerbated by COVID-19: AMR and COVID-19. J. Appl. Pharm. Sci. 2021, 11, 1–7. [CrossRef]

13. Knight, G.M.; Glover, R.E.; McQuaid, C.F.; Olaru, I.D.; Gallandat, K.; Leclerc, Q.J.; Fuller, N.M.; Willcocks, S.J.; Hasan, R.; van Kleef, E. Antimicrobial resistance and COVID-19: Intersections and implications. eLife 2021, 10, e64139. [CrossRef]

14. Langford, B.J.; So, M.; Raybardashan, S.; Leung, V.; Soucy, J.-P.R.; Westwood, D.; Daneman, N.; MacFadden, D.R. Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis. Clin. Microbiol. Infect. 2021, 27, 520–531. [CrossRef]

15. Ahmed, N.; Khalid, H.; Mushtaq, M.; Rabaan, A.A.; Garout, M.; Halwani, M.A.; Al Mutair, A.; Alhumaid, S.; Al Alawi, Z. The Molecular Characterization of Virulence Determinants and Antibiotic Resistance Patterns in Human Bacterial Uropathogens. Antibiotics 2022, 11, 516. [CrossRef]

16. Dray, S.; Coiffard, B.; Persico, N.; Papazian, L.; Hraiech, S. Are tracheal surveillance cultures useful in the intensive care unit?Ann. Transl. Med. 2018, 6, 421. [CrossRef]

17. Dani, A. Colonization and infection. Cent. Eur. J. Urol. 2014, 67, 86. [CrossRef]

18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.; CLSI Supplement M100: Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2019.

19. van Duin, D.; Barlow, G.; Nathwani, D. The impact of the COVID-19 pandemic on antimicrobial resistance: A debate. JAC-Antimicrob. Resist. 2020, 2, dliaa053. [CrossRef]

20. Khurana, S.; Singh, P.; Sharad, N.; Kiro, V.V.; Rastogi, N.; Lathwal, A.; Malhotra, R.; Trikha, A.; Mathur, P. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J. Med. Microbiol. 2021, 39, 147–153.

21. Lai, C.-C.; Wang, C.-Y.; Hsieh, F.-R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J. Microbiol. Immunol. Infect. 2020, 53, 505–512. [CrossRef]

22. Hoque, M.N.; Akter, S.; Mishu, I.D.; Islam, M.R.; Rahman, M.S.; Akhter, M.; Islam, I.; Hasan, M.M.; Rahman, M.M.; Sultana, M. Microbial co-infections in COVID-19: Associated microbiota and underlying mechanisms of pathogenesis. Microb. Pathog. 2021, 156, 104941. [CrossRef]
23. Wolfe, A.; Baunoch, D.; Wang, D.; Gnewuch, R.; Zhao, X.; Halverson, T.; Cacdac, P.; Huang, S.; Lauterbach, T.; Luke, N. Co-occurrence of SARS-CoV-2 and respiratory pathogens in the frail elderly. *medRxiv* 2020. [CrossRef]

24. Chong, W.H.; Saha, B.K.; Ramani, A.; Chopra, A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. *Infection* 2021, 49, 591–605. [CrossRef]

25. Vijay, S.; Bansal, N.; Rao, B.K.; Veeraraghavan, B.; Rodrigues, C.; Wattle, C.; Goyal, J.P.; Tadepalli, K.; Mathur, P.; Venkateswaran, R. Secondary infections in hospitalized COVID-19 patients: Indian experience. *Infect. Drug Resist.* 2021, 14, 1893. [CrossRef]

26. Kayarat, B.; Khanna, P.; Sarkar, S. Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We Stand? *Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care Med.* 2021, 25, 699.

27. Garcia-Vidal, C.; Sanjuan, G.; Moreno-García, E.; Puerta-Alcalde, P.; Garcia-Pouton, N.; Chumbita, M.; Fernandez-Pittol, M.; Pitart, C.; Inciarte, A.; Bodro, M. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. *Clin. Microbiol. Infect.* 2021, 27, 83–88. [CrossRef]

28. Bazaid, A.S.; Barnawi, H.; Qanash, H.; Alsaif, G.; Aldarhami, A.; Gattan, H.; Alharbi, B.; Alrashidi, A.; Al-Soud, W.A.; Moussa, S. Bacterial coinfection and antibiotic resistance profiles among hospitalised COVID-19 patients. *Microorganisms* 2022, 10, 495. [CrossRef]